Low expression of estrogen receptor β in T lymphocytes and high serum levels of anti-estrogen receptor α antibodies impact disease activity in female patients with systemic lupus erythematosus by Maselli, Angela et al.
RESEARCH Open Access
Low expression of estrogen receptor β in T
lymphocytes and high serum levels of anti-
estrogen receptor α antibodies impact
disease activity in female patients with
systemic lupus erythematosus
Angela Maselli1†, Fabrizio Conti2†, Cristiano Alessandri2, Tania Colasanti3, Cristiana Barbati3, Marta Vomero3,
Laura Ciarlo1, Mario Patrizio1, Francesca Romana Spinelli2, Elena Ortona3,4*, Guido Valesini2
and Marina Pierdominici3
Abstract
Background: Current evidence indicates that estrogens, in particular 17β-estradiol (E2), play a crucial role in the
gender bias of autoimmune diseases although the underlying molecular mechanisms have not yet been fully
elucidated. Immune cells have estrogen receptors (ERs), i.e., ERα and ERβ, that play pro- and anti-inflammatory
functions, respectively, and the presence of one estrogen receptor (ER) subtype over the other might change
estrogen effects, promoting or dampening inflammation. In this study, we contributed to define the influences of
E2 on T cells from female patients with systemic lupus erythematosus (SLE), a representative autoimmune disease
characterized by a higher prevalence in women than in men (female/male ratio 9:1). Particularly, our aim was to
evaluate whether alterations of ERα and ERβ expression in T cells from female SLE patients may impact lymphocyte
sensitivity to E2 and anti-ERα antibody (anti-ERα Ab) stimulation interfering with cell signaling and display a direct
clinical effect.
Methods: Sixty-one premenopausal female patients with SLE and 40 age-matched healthy donors were recruited.
Patients were divided into two groups based on the SLE Disease Activity Index 2000 (SLEDAI-2K) (i.e., <6 and ≥6).
ER expression was evaluated in T lymphocytes by flow cytometry, immunofluorescence, and Western blot analyses.
Serum anti-ERα Ab levels were analyzed by enzyme-linked immunosorbent assay (ELISA). ER-dependent signaling
pathways were measured by a phosphoprotein detection kit.
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Results: Intracellular ERβ expression was significantly lower in T cells from patients with SLEDAI-2K ≥6 as compared
with healthy donors and patients with SLEDAI-2K <6 and negatively correlated with disease activity. The expression
of intracellular and membrane-associated-ERα was similar in SLE and control T cells. ER-dependent signaling pathways
were activated in T cells from SLE patients with SLEDAI-2K ≥6, but not with SLEDAI-2K <6, when both membrane and
intracellular ERs were stimulated by co-treatment with E2 and anti-ERα Abs.
Conclusions: Our results demonstrate an altered ER profile in SLE patients, possibly contributing to SLE pathogenesis
and interfering with clinical activity, and highlight the potential exploitation of T cell-associated ERβ as a biomarker of
disease activity.
Keywords: Estrogen, Estrogen receptor, Anti-ERα antibodies, T lymphocytes, Systemic lupus erythematosus, Gender,
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Background
Most of autoimmune diseases are more common in
women and plausible mechanisms for this female pre-
dominance include hormonal and genetic factors.
Women tend to have a different age at onset and differ-
ent disease activity than men [1, 2]. Systemic lupus
erythematosus (SLE) is a multifactorial and highly poly-
morphic systemic autoimmune disease that predomin-
antly afflicts women of child-bearing age, where the
reported female:male ratio is 8–15:1 [3]. It tends to ex-
acerbate during pregnancy and to remit after meno-
pause. The precise etiology of SLE remains elusive;
however, it is known that a complex interaction between
genetic, environmental, and hormonal factors promotes
the immune dysfunction underlying the pathogenesis of
the disease [4]. Immunological defects include aberrant
function of T cells that provide help to autoreactive B
cells and infiltrate target tissue, production of a wide
array of autoantibodies by dysregulated B cells, forma-
tion of immune complex that, once deposited, cause tis-
sue injury. SLE most commonly affects the skin and
kidneys but can manifest anywhere in the body. Studies
in animal models and humans suggest that estrogens, in
particular 17β-estradiol (E2), play an important role in
the female preponderance observed in SLE and in dis-
ease activity although the underlying molecular mecha-
nisms have not yet been fully elucidated [5]. Estrogens
have a complex role in inflammation [6] and most of
their effects are mediated by two specific intracellular re-
ceptors, i.e., estrogen receptor (ER)α and ERβ, which
function as ligand-activated nuclear transcription factors
producing genomic effects [7]. Estrogen receptors are
expressed in different cell types including immune cells
[7–9] and the presence of one ER subtype over the other
might change estrogen effects, promoting or dampening
inflammation [6]. Several studies with mouse models of
SLE have suggested a prominent pro-inflammatory role
for ERα, contributing to disease progression [10–12]. In
particular, ERα deficiency in lupus mice attenuates glom-
erulonephritis and increases survival [10]. Accordingly,
treatment of lupus mice with the ERα-selective agonist
propyl pyrazole triol leads to an accelerated disease
course and a shortened survival time [11]. On the other
hand, ERβ appears to have an anti-inflammatory and im-
munosuppressive effect on lupus mice and administra-
tion of the ERβ-selective agonist diarylpropionitrile
(DPN) leads to a reduction of autoantibody production
and an amelioration of albuminuria [11]. The discovery
of membrane-associated ERα (mERα) in different cell
types, including lymphocytes [9], has greatly expanded
the understanding of estrogen action [13]. Membrane
ERα rapidly activates different protein kinase cascades
influencing downstream transcription factors to produce
non-genomic effects; at the same time, it can modulate
intracellular ER action through the phosphorylation of
intracellular ERs and their co-activators [14]. The identi-
fication in SLE patients of serum autoantibodies that
react with mERα (anti-ERα Abs) and act as estrogen ag-
onists [15] has made the scenario even more complex,
opening a new path for the research in the estrogen-
related receptor activity. To gain additional insight into
the mechanisms underlying E2 effects in SLE pathogen-
esis, we evaluated in T lymphocytes from female SLE pa-
tients the occurrence of alterations of ER expression and
ER-dependent signaling pathways activated by E2 and/or
anti-ERα Abs. We also evaluated the potential associ-
ation between ER expression levels and disease activity
to assess the potential role of ERs as biomarkers of dis-
ease activity in SLE.
Methods
Patients and biologic samples
Sixty-one premenopausal female patients with SLE, diag-
nosed according to the American College of Rheumatol-
ogy (ACR) revised criteria [16], were recruited in this
study. The age of participants ranged between 25 and
47 years with a median age of 38 years. All of the pa-
tients attended the Lupus Clinic, Rheumatology Unit,
Sapienza University of Rome. The control group con-
sisted of 40 age-matched healthy females. Informed
Maselli et al. Biology of Sex Differences  (2016) 7:3 Page 2 of 10
consent was obtained from each subject, and the Ethical
Committee of "Policlinico Umberto I", Rome, Italy ap-
proved the study. Disease activity was scored on the
basis of the SLE Disease Activity Index 2000 (SLEDAI-
2K) [17]. Median SLEDAI-2K score was 2 (range 0–23).
The SLE patients were categorized into two groups on
the basis of SLEDAI-2K scores, i.e., <6 (n = 38) and ≥6
(n = 23). No participant was taking hormone replace-
ment therapy or oral contraceptives. Forty-two patients
were taking anti-malarials, 43 were taking prednisone at
a dosage ranging from 7.5 to 262.5 mg for week and 20
were using immunosuppressive drugs (13 were taking
mycophenolate, 3 were taking cyclosporine, 3 were tak-
ing azathioprine, and 1 patient was taking methotrexate).
Table 1 summarizes clinical and serological features and
current treatment of the patient population. Sera were
obtained by standard methods and stored at –80 °C until
used.
ELISA
Enzyme-linked immunosorbent assay (ELISA) was de-
veloped as previously described [15]. Briefly, polystyrene
plates (Maxisorp, Nunc, Roskilde, Denmark) were coated
with the antigen (2 μg/well ERα, Sigma, St. Louis, MO)
in 0.05 M NaHCO3 buffer, pH 9.5, and incubated over-
night at 4 °C. The plates were blocked with 100 μl/well
of 3 % milk, for 1 h at 37 °C. Human sera were diluted
in PBS-Tween and 1 % milk (1:100 for total IgG), 100 μl
per well. Peroxidase-conjugated goat anti-human IgG
(Bio-Rad Laboratories, Richmond, CA) were diluted in
PBS-Tween containing 1 % milk (1:3000) and incubated
for 1 h at room temperature. O-phenylenediamine dihy-
drochloride (Sigma) was used as a substrate, and the op-
tical density was measured at 490 nm (optical density
(OD)490). Mean + 3 standard deviations of the OD read-
ing of the healthy donors was considered as the cutoff
level for positive reactions. All assays were performed in
quadruplicate. Data were presented as the mean OD
corrected for background (wells without coated antigen).
Purification of anti-ERα Abs from patients’ sera
Antibody purification was performed as previously de-
scribed [15]. Briefly, recombinant ERα (50 μg, Sigma)
was spotted onto a nitrocellulose filter and incubated
with sera from 10 SLE patients that had an OD >0.5 by
ELISA. The antibodies were eluted with 100 mM glycine,
pH 2.5, immediately neutralized with 1 M Tris-HCl,
pH 8, and dialyzed against PBS. Endotoxin contamin-
ation of antibodies was determined by the quantitative
chromogenic Limulus amebocyte cell lysate assay (QCL-
1000; BioWhittaker, Walkersville, MD). Antibodies from
a preparation of intravenous immunoglobulin (IVIG)
precipitated by saturated ammonium sulfate solution
were used as control.
Isolation of peripheral blood mononuclear cells and cell
culture conditions
Peripheral blood mononuclear cells were isolated by
Ficoll-Hypaque density gradient centrifugation and sep-
aration of untouched T cells was performed using the
Pan T Cell isolation Kit II (Miltenyi Biotec, Bergisch-
Gladbach, Germany). The purity of recovered cells,
assessed by flow cytometer, was ≥97 %. Cells were cul-
tured in RPMI-1640 medium without phenol red (Gibco
BRL, Grand Island, NY) supplemented with 10 %
charcoal-stripped FBS (Euroclone, Pero, Milan, Italy),
2 mM glutamine (Sigma), and 50 μg/ml gentamycin
(Sigma). For phosphoprotein assay, T cells were cultured
for 24 h; E2 (10 nM, Sigma) was added at the beginning
of cell culture whereas human anti-ERα Abs (50 μg/ml)
Table 1 Clinical and serological features and current therapy of
SLE patients
Characteristic
Height (mean ± standard deviation; cm) 163 ± 6
Weight (mean ± standard deviation; kg) 59 ± 9
Body mass index (mean ± standard deviation) 23 ± 4
Acute cutaneous lupus [n/tot (%)] 28/61 (46)
Subacute cutaneous lupus [n/tot (%)] 11/61 (18)
Discoid lupus [n/tot (%)] 5/61 (8)
Photosensitivity [n/tot (%)] 31/61 (51)
Serositis [n/tot (%)] 12/61 (20)
Neuropsychiatric lupus [n/tot (%)] 2/61 (3)
Arthritis [n/tot (%)] 39/61 (64)
Glomerulonephritis [n/tot (%)] 20/61 (33)
Hematological features [n/tot (%)] 32/61 (52)
Arterial thrombosis [n/tot (%)] 1/61 (2)
Venous thrombosis [n/tot(%)] 1/61 (2)
Pregnancy morbidity [n/tot (%)] 6/61 (10)
Secondary anti-phospholipid syndrome [n/tot (%)] 6/61 (10)
ANA [n/tot (%)] 61/61 (100)
Anti-dsDNA [n/tot (%)] 46/61 (75)
Anti-Sm [n/tot (%)] 20/61 (33)
LA [n/tot (%)] 11/61 (18)
aCL IgG [n/tot (%)] 15/61 (25)
aCL IgM [n/tot(%)] 13/61 (21)
aβ2GPI IgG [n/tot (%)] 9/61 (15)
aβ2GPI IgM [n/tot (%)] 6/61 (10)
Anti-malarials [n/tot (%)] 42/61 (69)
Prednisone [n/tot (%)] 43/61 (70)
Immunosuppressants [n/tot (%)] 20/61 (33)
ANA anti-nuclear antibodies, anti-dsDNA anti-double stranded DNA antibodies,
anti-Sm anti-Smith antibodies, LA lupus anticoagulant antibodies, aCL anti-
cardiolipin antibodies, aβ2GPI anti-β2 glycoprotein I antibodies
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or equal amount of IVIG were added 30 min before the
end of incubation time. T cells were also treated as de-
scribed above plus 10-fold molar excess of the high-
affinity estrogen receptor antagonist ICI 182,780 (Tocris,
Ellisville, MO). To selectively stimulate ERβ, purified T
lymphocytes were treated for 48 h with the ERβ agonist
DPN (10 nM, Sigma). In this regard, for cytokine pro-
duction analysis, untreated or DPN-treated cells were
activated with 25 ng/ml phorbol myristate acetate
(PMA, Sigma) and 1 μg/ml ionomycin for the last 16 h
of culture (IFN-γ, IL-2, and IL-4 analysis) or with 50 ng/
ml PMA (Sigma) and 1 μg/ml ionomycin (Sigma) for the
last 4 h of culture (IL-17 analysis). To inhibit cytokine
secretion, 10 μg/ml brefeldin A (Sigma) was added to
each condition at the beginning of stimulation with
PMA plus ionomycin.
Flow cytometry
Surface and intracellular phenotyping of T cells was
performed by flow cytometry as previously described
[9, 18]. Allophycocyanin-conjugated anti-CD3, allophy-
cocyanin- or phycoerythrin (PE)-conjugated anti-CD4,
peridinin chlorophyll protein-conjugated anti-CD8,
fluorescein isothiocyanate (FITC)-conjugated anti-
CD95, PE-conjugated anti-CD25, PE-conjugated anti-
HLA-DR, FITC-conjugated anti-IFN-γ, PE-conjugated
anti-IL-4 (BD Biosciences, San Jose, CA), FITC-
conjugated anti-IL-17A (eBioscience, San Diego, CA),
anti-ERα (clone C-542, Abcam, Cambridge, UK), and
anti-ERβ (clone 1531, Santa Cruz Biotechnology, Santa
Cruz, CA) monoclonal (m)Abs were used. Anti-ER Abs
were visualized by FITC-conjugated F(ab’)2 fragment
secondary Ab (Abcam). Equal amount of mouse IgG
isotype controls were run in parallel. To determine the
frequency of T cell subsets, total lymphocytes were first
gated by forward and side scatter and then additionally
gated for CD4 or CD8 molecule expression. Acquisition
was performed on a FACSCalibur flow cytometer (BD
Biosciences) and 50,000 events per sample were run.
Data were analyzed using the Cell Quest Pro software
(BD Biosciences).
Immunofluorescence analysis
Immunofluorescence analysis was performed as previ-
ously described [9]. Briefly, purified T lymphocytes were
fixed with 4 % formaldehyde and permeabilized with
0.5 % Triton X-100 in PBS. Cells were stained with anti-
ERα (clone C542, Abcam) or anti-ERβ mAbs (clone
1531, Santa Cruz Biotechnology) and then incubated
with Alexa Fluor 488-coniugated secondary antibody
(Molecular Probes, Eugene, OR). Nuclei were counter-
stained with Hoechst 33342 (Molecular Probes). Fluores-
cence was analyzed with an Olympus U RFL microscope
(Olympus, Hamburg, Germany).
SDS-PAGE and Western blot
SDS-PAGE and Western blot were performed as previ-
ously described [9]. Briefly, purified T cells were lysed in
RIPA buffer (100 mM Tris-HCl, pH 8, 150 mM NaCl,
1 % Triton X-100, 1 mM MgCl) in the presence of
complete protease inhibitor mixture. Protein content
was determined by the Bradford assay (Bio-Rad Labora-
tories). Lymphocyte lysates (30 μg/ml) were loaded in
10 % SDS-PAGE. Anti-ERα (clone F-10) and anti-ERβ
(clone 1531) mAbs (both from Santa Cruz Biotechnol-
ogy) were used as primary Abs. Peroxidase-conjugated
goat anti-mouse IgG was used as secondary Ab (Bio-Rad
Laboratories), and the reactions were developed using
the SuperSignal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL). To ensure the presence of equal
amounts of protein, the membranes were reprobed with
a rabbit anti-human glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) Ab (Sigma). Quantification of
protein expression was performed by densitometry ana-
lysis of the autoradiograms (GS-700 Imaging Densitom-
eter, Bio-Rad Laboratories).
Phosphoprotein assay
A commercially available multiplex bead-based im-
munoassay kit (Bio-Plex Phosphoprotein Detection Kit,
Bio-Rad Laboratories) was used according to the manu-
facturer’s protocol to detect the phosphorylation of the
mitogen-activated protein kinases extracellular signal-
regulated kinase (ERK) and C-Jun N-terminal kinase
(JNK), protein kinase B (Akt), and nuclear factor kappa
B (NF-kB) in lysates from purified T lymphocytes ob-
tained from SLE patients treated as described above.
Data were analyzed with Bio-Plex manager software,
version 4.1.1 (Bio-Rad Laboratories) and reported as
fluorescence intensity (FI). Values with a coefficient of
variation >12 % were excluded.
Statistics
Statistical significance was determined using the Mann-
Whitney U test. Correlations were evaluated by using
Spearman’s rank correlation test. Linear regression ana-
lysis was used to display a best fit line to the data. Statis-
tical analyses were performed using GraphPad Prism,
version 5.0 software (GraphPad Software, San Diego,
CA). All tests were two-sided, and a p value <0.05 was
considered statistically significant.
Results
Intracellular ERβ expression was reduced in peripheral
blood T lymphocytes from SLE patients with SLEDAI-2K
scores ≥6 and correlated with disease activity
We first compared the intracellular ERα and ERβ ex-
pression in T cells from patients with SLE and healthy
controls by flow cytometry and immunofluorescence
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analyses. Our results indicated that SLE patients showed
a greater variability in the expression of ERα (Fig. 1a, left
panel) and ERβ (Fig. 1b, left panel) as compared to
healthy controls, and no significant differences were de-
tected between these two groups. To estimate whether
ER expression level may reflect disease activity, SLE pa-
tients were categorized into two groups according to the
SLEDAI-2K score at the time of sampling: <6 (inactive/
low disease activity) and ≥6 (moderate/high disease ac-
tivity). No statistically significant differences were de-
tected for ERα expression between SLE T cells from
patients with SLEDAI-2K scores ≥6 and those with
SLEDAI-2K scores (Fig. 1a, c, left panels).
Additionally, Spearman’s rank analysis did not show
any correlation between ERα levels and the SLEDAI-2K
score (Fig. 1a, right panel). Differently, a significant
lower expression of ERβ was found in T cells from pa-
tients with SLEDAI-2K scores ≥6 as compared to those
with SLEDAI-2K scores <6 (p = 0.0001) and healthy con-
trols (p = 0.0032) (Fig. 1b, left panel and Fig. 1c, right
panel). Accordingly, a significant negative correlation be-
tween ERβ expression in SLE T cells and the SLEDAI-
2K score was found (Fig. 1b, right panel, R = −0.56; p =
0.0001). Western blot analysis of total amount of ERα
and ERβ in T cells from SLE patients and healthy con-
trols confirmed the above reported results (Additional
A
B
C
D
Fig. 1 Evaluation of intracellular ER expression levels in T lymphocytes from SLE patients and healthy controls. a Intracellular ERα and b intracellular ERβ
expression levels were evaluated by flow cytometry. Values of ER/isotype control mean fluorescence intensity ratio (rMFI) are reported, and data are
represented as box plots displaying medians, 25th and 75th percentiles as boxes, and the lowest and highest values as whiskers. Statistical differences were
calculated by the Mann-Whitney U test. Correlations of intracellular ERα and ERβ expression levels with the SLEDAI-2K score are also shown. The Spearman’s
rho (R) and p values were determined using the Spearman’s rank correlation analysis. Solid lines represent best fits as estimated by linear regression analysis.
c Immunofluorescence analysis of intracellular ERα (left panels) and ERβ (right panels) expression (green). Representative images of T lymphocytes from the
studied populations are shown. Cell nuclei were stained with Hoechst 33342 in blue. Magnification, ×2200. d ERα/ERβ ratio and its correlation with the
SLEDAI-2K score are shown. Data are represented and analyzed as described above. ctrs healthy controls, iER intracellular ER, SLEDAI-2K Systemic Lupus
Erythematosus Disease Activity Index 2000
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file 1: Figure S1). Furthermore, the differential expres-
sion of ERβ in SLE T cells and its correlation with dis-
ease activity were also observed when CD4+ and CD8+
T cells were considered separately (Additional file 2:
Figure S2). As a result of the minor expression of ERβ in
SLE patients with SLEDAI-2K scores ≥6, an increased
ERα/ERβ ratio was detected in T lymphocytes from this
group of patients as compared to those with SLEDAI-2K
scores <6 (p = 0.0016) and healthy controls (p = 0.0249),
Fig. 1d (left panel). ERα/ERβ ratio also positively corre-
lated with the SLEDAI-2K score (Fig. 1d, right panel, R
= 0.36; p = 0.0213). For both ERα and ERβ expression,
no further significant associations were found with the
epidemiological and clinical parameters evaluated in the
present study. In particular, when patients were divided
according to the type of medications and dosage sched-
ule (for prednisone, < and ≥7.5 mg/die) at the time of
the enrollment, no differences were found for ERα and
ERβ expression among the analyzed groups (data not
shown).
To evaluate whether the differential expression of ERβ
in SLE T cells from patients with SLEDAI-2K scores ≥6
and those with SLEDAI-2K scores <6 could affect T cell
response to the ERβ-selective agonist DPN, purified T
cells from SLE patients were treated with this compound
and analyzed for the expression of activation markers,
i.e., CD25, HLA-DR, and CD95 molecules, and the
production of a panel of cytokines, i.e., IFN-γ, IL-4, and
IL-17. As shown in Fig. 2, DPN treatment induced a sig-
nificant reduction (p < 0.05) of CD25 and HLA-DR ex-
pression markers both in CD4+ and CD8+ T cells from
SLE patients with SLEDAI 2K scores <6 but not in those
with SLEDAI-2K scores ≥6, suggesting that a low ex-
pression of ERβ could affect the responsiveness to select-
ive ERβ stimulation. Regarding cytokine production, no
significant changes were found in treated versus un-
treated cells, in both groups of patients (Additional file 3:
Figure S3).
Expression of mERα did not differ in SLE and normal T cells
As a further step, we compared the expression of mERα
on T cells from patients with SLE and healthy controls
and we found that the level of this receptor was compar-
able in these two groups (Fig. 3a). When the patients
were divided into two groups according to the SLEDAI-
2K score (i.e., SLEDAI-2K scores <6 and ≥6), no differ-
ences in the expression of mERα between the patients’
subgroups were observed (Fig. 3a). No positivity for
mERβ expression was detected in all the studied popula-
tions (data not shown). Confirming our previously pub-
lished results [15], patients with SLE showed detectable
serum levels of anti-ERα Abs (Fig. 3b) and a significant
Fig. 2 Flow cytometry immunophenotyping of DPN-treated T lymphocytes. Flow cytometry analysis of T cell activation markers was carried out
in CD4+ and CD8+ T lymphocytes from randomly selected SLE patients with SLEDAI-2K <6 and ≥6 (n = 5 for group), arbitrarily chosen as representative
of the whole series, and treated with DPN (10 nM) for 48 h. Data are represented as box plots displaying medians, 25th and 75th percentiles as boxes,
and the lowest and highest values as whiskers. *p < 0.05 versus untreated cells
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difference in the presence of these antibodies between
patients with SLEDAI-2K scores <6 and ≥6 was observed
(p = 0.0002, Fig. 3b). Anti-ERα Ab serum levels signifi-
cantly correlated with disease activity (R = 0.35; p =
0.006, Fig. 3c). No correlation was found between mERα
expression and anti-ERα Ab serum levels as well as the
epidemiological and clinical parameters of the patient
population.
ER-dependent signaling pathways in SLE T cells are
influenced by disease activity
Based on the above reported data showing a significant
negative correlation between ERβ expression and
SLEDAI-2K score on the one hand and a significant
positive correlation between anti-ERα Ab serum levels
and SLEDAI-2K score on the other hand, we compared
in T cells from SLE patients with SLEDAI-2K scores <6
and ≥6 the impact of these antibodies and/or E2 on ER-
dependent signaling pathways. In particular, we analyzed
the activation status of proteins involved in signaling
pathways classically targeted by E2 and described as dys-
regulated in SLE T cells (i.e., the mitogen-activated pro-
tein kinases ERK and JNK, Akt, and NF-kB) [19–21]. As
shown in Fig. 4a–d, following stimulation with E2 and
anti-ERα Abs, ERK, JNK, Akt, and NF-kB activities sig-
nificantly increased in T cells from patients with
SLEDAI-2K scores ≥6 (p ≤ 0.01 versus untreated cells),
whereas no changes were detectable in those from pa-
tients with SLEDAI-2K scores <6. Notably, kinase activ-
ity was increased when E2 and anti-ERα Abs were added
together but not when the reagents were added alone,
suggesting that both membrane and intracellular ER ac-
tivation are required to observe this effect. To exclude
that the modulation of JNK, ERK, Akt, and NF-kB phos-
phorylation could be due to contaminants in cell culture,
we treated SLE T cells with E2 and anti-ERα Abs plus
the high-affinity estrogen receptor antagonist ICI
182,780. Addition of this compound to T cells from pa-
tients with SLEDAI-2K scores ≥6 significantly reduced
(p < 0.05) the level of protein phosphorylation in re-
sponse to ER activation, supporting the specific role of
ER in the observed effect (Fig. 4e).
Discussion
In this study, we characterized the ER profile of T cells
from female SLE patients and the susceptibility of these
cells to E2 and anti-ERα Ab stimulation, taking into ac-
count disease activity. Growing evidence suggests that
ER subtypes mediate distinct transcriptional activities
when they are co-expressed in the same cells and that
the quantity and distribution of these receptors are cru-
cial for their biological effects [6]. Thus, the analysis of
ERα and ERβ expression in lymphocytes from SLE pa-
tients may provide a useful tool in understanding the
A
B
C
Fig. 3 Membrane-associated ERα expression levels and anti-ERα Ab
levels. a Membrane-associated ERα expression levels were evaluated
by flow cytometry. Values of mERα/isotype control mean fluorescence
intensity ratio (rMFI) are reported, and data are represented as box
plots displaying medians, 25th and 75th percentiles as boxes, and the
lowest and highest values as whiskers. b Anti-ERα Abs (median with
range) in sera from patients with SLE and healthy controls. Samples
were considered positive if the OD at 490 nm was higher than the
cutoff value of an OD at 490 nm of 0.2 (broken line). The cutoff value
was defined as 3 SD above the mean OD at 490 nm in healthy controls.
Circles represent individual samples. c Correlation of anti-ERα Ab levels
with the SLEDAI-2K score. The Spearman’s rho (R) and p values were
determined using the Spearman’s rank correlation analysis. Solid lines
represent best fits as estimated by linear regression analysis. ctrs healthy
controls, mERα membrane-associated ERα, OD optical density, SLEDAI-2K
Systemic Lupus Erythematosus Disease Activity Index 2000
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responsiveness of these cells to estrogens. In the current
study, we observed that the expression of intracellular
ERβ was significantly reduced in T cells from SLE pa-
tients with SLEDAI-2K scores ≥6 as compared to those
with SLEDAI-2K scores <6 and healthy controls. Import-
antly, a negative correlation between intracellular ERβ
expression levels and the SLEDAI-2K score was found.
No significant difference was detectable for intracellular
and membrane ERα expression between T cells from
SLE patients and those from healthy controls. According
to what observed by us, Inui et al. [22] found a de-
creased expression of ERβ mRNA level in peripheral
blood mononuclear cells from SLE patients as compared
with those from normal controls and a significant in-
verse correlation between ERβ mRNA expression level
and the SLEDAI score. In contrast, Rider et al. [23] did
A
C
B
D
E
Fig. 4 Analysis of ER-dependent signaling pathways in T cells from SLE patients. a–d A panel of phosphoproteins was measured using the Bio-
Plex Multiplex Phosphoprotein Assay in T cell lysates from randomly selected SLE patients with SLEDAI-2K <6 and ≥6 (n = 5 for group), arbitrarily
chosen as representative of the whole series, after cell treatment with IVIG, E2, anti-ERα Abs, and E2 plus anti-ERα Abs (see the “Methods” section
for details). The fluorescence intensity (FI) of a phospho (p)-ERK, b p-JNK, c p-Akt, and d p-NF-kB was measured and data are presented as mean ± SD.
*p < 0.01 versus untreated cells. e Activation of ER with the abovementioned treatments was antagonized by addition of 10-fold molar excess of the
high-affinity estrogen receptor antagonist ICI 182,780 in T cells from patients with SLEDAI-2K scores ≥6. Data are presented as mean ± SD. #p < 0.05
versus E2 plus anti-ERα Abs
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not find any significant difference between SLE and nor-
mal T cells in the level of both ERα and ERβ and any
association between ER expression and disease activity.
In this regard, the discrepancy between our results and
those of Rider et al. [23] may be mainly due to the small
number of patients enrolled in this latter study. Interest-
ingly, in a recent study by our group, a significant
reduction of ERβ expression has been observed in T
lymphocytes from patients affected by Crohn disease or
ulcerative colitis with active disease as compared to
those in remission [24]. In addition, a pro-inflammatory
microenviroment has been found to be involved in the
downregulation of ERβ [24]. Thus, it is tempting to
speculate that also in SLE, the alteration of ERβ expres-
sion could be a consequence of the chronic inflamma-
tion underlying the active state of the disease. Thus, our
results showing a negative correlation between ERβ ex-
pression and disease activity open a new path for future
research aimed at better defining the role of ERβ in SLE
pathogenesis and points to this receptor as a potential
marker for disease activity.
In a previous paper, we observed that anti-ERα Abs
detectable in sera from SLE patients significantly corre-
lated with disease activity. These autoantibodies act as
estrogen agonists, inducing ERK phosphorylation in
freshly isolated T cells from healthy controls [15]. In this
study, we observed that anti-ERα Abs in the presence of
E2, thus mimicking the in vivo physiological conditions
of premenopausal women with SLE, were able to acti-
vate ER-dependent signaling pathways, i.e., ERK, JNK,
Akt, and NF-kB, in T lymphocytes from patient with
SLEDAI-2K scores ≥6 but not from those with SLEDAI-
2K scores <6. To note, all these signaling pathways are
involved in the induction and maintenance of T cell self-
tolerance [25–27] and their aberrant expression has been
described in several autoimmune diseases including SLE
where increased ERK and JNK activities have been found
to correlate with disease activity [28]. Our results sug-
gest that the imbalance in the expression of ER subtypes,
i.e., the low expression of the anti-inflammatory ERβ
and the consequent predominance of ERα signaling, in
T cells from female patients with active SLE may impact
lymphocyte sensitivity to E2 and to anti-ERα Ab stimu-
lation, interfering with cell signaling and contributing to
inflammation and disease activity.
In this paper, we focused on female SLE patients.
However, SLE can also occur in males that have a late
onset and different clinical features and outcomes, sug-
gesting that distinct male-specific predisposing and/or
pathogenetic factors exist [29]. Further studies are re-
quired to understand the sex-related aspects of SLE
disease susceptibility, clinical features, and outcome, po-
tentially providing new tools for clinical intervention
according to sex.
Conclusions
We provide evidence that ER profile is altered in T cells
from female SLE patients and that the extent of ERβ ex-
pression reflects disease activity. Additionally, we pro-
vide evidence that a different sensitivity of T cells to ER
stimulation exists between SLE patients with high versus
low disease activity. A deep characterization of factors
controlling ER expression and function may increase our
knowledge on the pathogenesis of SLE and open new
perspectives for the comprehension and management of
the disease. Further analysis using ERα- and ERβ-
selective agonists will allow to more deeply investigate
the ER-mediated responses elicited in chronic inflamma-
tory conditions and to study the potential role of ER as
therapeutic target. Moreover, further longitudinal studies
are mandatory in order to validate our results and trans-
late them in the clinical practice, assessing the possibility
of using ERβ as prognostic marker in female SLE.
Additional files
Additional file 1: Figure S1. ERα and ERβ Western blot analysis of T-
cell lysates from SLE patients and healthy controls. The expression of ERα
and ERβ was evaluated in T lymphocytes from SLE patients, divided in
patients with SLEDAI-2K scores <6 and ≥6 and healthy controls (n = 5
subjects for group). A Data from representative subjects are shown. B
Densitometry analysis of protein levels relative to GAPDH is also shown.
Values are expressed as mean ± SD. Statistical differences were calculated
by the Mann-Whitney U test. *p < 0.001 versus healthy controls and patients
with SLEDAI-2K scores <6. Ctrs, healthy controls. (PPT 182 kb)
Additional file 2: Figure S2. Flow cytometry analysis of intracellular
ERβ expression levels in CD4+ and CD8+ T lymphocytes from SLE
patients and healthy controls. Intracellular ERβ expression levels were
evaluated by flow cytometry in CD4+ (A, left panel) and CD8+ (B, left
panel) T lymphocytes from SLE patients, considered as a whole or
divided in patients with SLEDAI-2K scores <6 and ≥6 and healthy controls.
Values of ERβ/isotype control mean fluorescence intensity ratio (rMFI) are
reported, and data are represented as box plots displaying medians, 25th
and 75th percentiles as boxes, and the lowest and highest values as
whiskers. Statistical differences were calculated by the Mann-Whitney U test.
Correlations of intracellular ERβ expression levels in CD4+ (A, right panel)
and CD8+ (B, right panel) T lymphocytes from SLE patients with the SLEDAI-
2K score are also shown. The Spearman’s rho (R) and p values were
determined using the Spearman’s rank correlation analysis. Solid lines
represent best fits as estimated by linear regression analysis. Ctrs, healthy
controls; iER, intracellular ER; SLEDAI-2K, Systemic Lupus Erythematosus
Disease Activity Index 2000. (PPTX 152 kb)
Additional file 3: Figure S3. Flow cytometry immunophenotyping of
DPN-treated T lymphocytes. Flow cytometry analysis of cytokine expression
at the single cell level was carried out in CD4+ and CD8+ T lymphocytes
from randomly selected SLE patients with SLEDAI-2K <6 and ≥6 (n = 5 for
group), arbitrarily chosen as representative of the whole series, and treated
with DPN (10 nM) for 48 h. For CD4+ and CD8+ T lymphocyte subsets, data
were expressed as the percentage of each subset within the CD4+ or CD8+
population considered as 100 %. Data are represented as box plots
displaying medians, 25th and 75th percentiles as boxes, and the lowest
and highest values as whiskers. (PPTX 169 kb)
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